Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Tumor Cells

Jeffrey Chalmers's Biography



Jeffrey Chalmers, Professor, Ohio State University

Jeff Chalmers is a Professor in the Department of Chemical and Biomolecular at The Ohio State University. In addition to a Professor, he is also Director of the Analytical Cytometery Shared Resource which is part of the Ohio State University Comprehensive Cancer Center and the Ohio State University Medical School. In his 23 years at Ohio State, he has received a National Science Foundation Young Investigator Award, was elected a Fellow of American Institute for Medical and Biological Engineering in 2001, and in 2005 was elected to the American Association for the Advancement of Science. He has published over 100 peer reviewed articles in bioengineering, and over 30 of these papers, 9 nine patents, and one book, are in the area of magnetic cell separation. Professor Chalmers received his Ph.D. from Cornell University in 1988 and his B.S. in Chemical Engineering from U.C. Berkeley and a B.A. from Westmont College in 1983.

Jeffrey Chalmers Image

Expanding the Definition of Traditional Circulating Tumor Cells (CTCs): Cells Associated With Cancer in the Blood of Patients With Solid Tumors

Friday, 3 February 2012 at 10:00

Add to Calendar ▼2012-02-03 10:00:002012-02-03 11:00:00Europe/LondonExpanding the Definition of Traditional Circulating Tumor Cells (CTCs): Cells Associated With Cancer in the Blood of Patients With Solid Tumors Circulating Tumor Cells in San Diego, USASan Diego, USASELECTBIOenquiries@selectbiosciences.com

The currently accepted definition of CTCs are cells that have: a nuclei, cytokeratin+ EpCAM+, and CD45-. Emerging evidence suggests that other rare, cancer associated circulating cells are present in the blood of metastatic cancer patients including CD45+ cytokeratin+ cells. A negative depletion process to isolate and quantify circulating tumor cells from the blood of head and neck cancer patients, using immunomagnetic separation was developed and is currently being validated on a number of solid tumors, including SCCHN and Breast Cancer. Correlation of number of CTCs, (tradition definition) tumor site, tumor stage, nodal status, smoking/alcohol abuse, histopathological characteristics, and clinical outcome was made with the SCCHN patients. In addition, the isolation of these cells is being used to measure the effectiveness of experimental drug combinations in a NCI approved study.


Add to Calendar ▼2012-02-02 00:00:002012-02-03 00:00:00Europe/LondonCirculating Tumor CellsCirculating Tumor Cells in San Diego, USASan Diego, USASELECTBIOenquiries@selectbiosciences.com